Reasons why stroke trials underestimate the neuroprotective effects of drugs.
Spedding
Michael
M
D000208:Acute Disease; D000368:Aged; D000818:Animals; D002241:Carbohydrates / Q000097:blood; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007511:Ischemia / Q000188:drug therapy; D008954:Models, Biological; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018579:Patient Selection; D010879:Piperazines / Q000627:therapeutic use; D012107:Research Design; D020521:Stroke / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D013997:Time Factors
D002241:Carbohydrates; D007093:Imidazoles; D018696:Neuroprotective Agents; D010879:Piperazines; C067927:lifarizine